Semaglutide Improves Heart and Kidney Health in Real-World Diabetes Patients

Type 2 diabetes (T2D) is a major component of cardiovascular-kidney-metabolic (CKM) syndrome, a complex condition increasing risks for heart and kidney disease. While clinical trials have shown semaglutide offers benefits beyond just blood sugar control and weight loss, most real-world studies have not thoroughly assessed its broader impact on cardiometabolic and renal outcomes. This study aimed to fill that gap by examining these broader effects in a real-world setting.

The study revealed significant improvements in both renal and cardiovascular markers over time. The mean change in urine albumin-to-creatinine ratio (UACR), a key indicator of kidney damage, showed a substantial reduction of -20.13 mg/g in the first year (p<0.001) and an even greater reduction of -54.03 mg/g in the second year (p<0.001). This indicates a significant improvement in kidney health. The event rate for 3-point Major Adverse Cardiovascular Events (MACE), which includes heart attack, stroke, and cardiovascular death, decreased from 26.82 per 1000 person-years (PY) at baseline to 22.31 per 1000 PY in the second year, indicating a notable improvement in cardiovascular safety. These findings suggest that semaglutide's benefits extend beyond glycemic and weight control, positively impacting critical cardiometabolic and renal health outcomes in a real-world setting.